These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 24834982

  • 21. Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits.
    Kato M, Sada T, Mizuno M, Kitayama K, Inaba T, Koike H.
    J Cardiovasc Pharmacol; 2005 Oct; 46(4):556-62. PubMed ID: 16160612
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
    Pugsley MK.
    Proc West Pharmacol Soc; 2005 Oct; 48():35-8. PubMed ID: 16416656
    [Abstract] [Full Text] [Related]

  • 25. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
    Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, Rakugi H, Ogihara T, Horiuchi M.
    Hypertension; 2004 Feb; 43(2):263-9. PubMed ID: 14707152
    [Abstract] [Full Text] [Related]

  • 26. Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats.
    Kadowaki D, Anraku M, Tasaki Y, Taguchi K, Shimoishi K, Seo H, Hirata S, Maruyama T, Otagiri M.
    Biol Pharm Bull; 2009 Dec; 32(12):2041-5. PubMed ID: 19952425
    [Abstract] [Full Text] [Related]

  • 27. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
    Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K.
    Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251
    [Abstract] [Full Text] [Related]

  • 28. Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan.
    Kiya Y, Miura S, Fujino M, Imaizumi S, Karnik SS, Saku K.
    Clin Exp Hypertens; 2010 Jan; 32(2):129-36. PubMed ID: 20374187
    [Abstract] [Full Text] [Related]

  • 29. Effects of olmesartan on arterial stiffness in rats with chronic renal failure.
    Chuang YC, Wu MS, Su YK, Fang KM.
    Cardiovasc Diabetol; 2012 Jun 13; 11():66. PubMed ID: 22694778
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
    Guerard P, Rakotoniaina Z, Goirand F, Rochette L, Dumas M, Lirussi F, Bardou M.
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep 13; 373(6):401-14. PubMed ID: 16896805
    [Abstract] [Full Text] [Related]

  • 32. Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial.
    Lorenzen JM, Neunhöffer H, David S, Kielstein JT, Haller H, Fliser D.
    Atherosclerosis; 2010 Mar 13; 209(1):184-8. PubMed ID: 19801149
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Olmesartan ameliorates urinary dysfunction in the spontaneously hypertensive rat via recovering bladder blood flow and decreasing oxidative stress.
    Shimizu S, Saito M, Oiwa H, Ohmasa F, Tsounapi P, Oikawa R, Dimitriadis F, Martin DT, Satoh I, Kinoshita Y, Tomita S.
    Neurourol Urodyn; 2014 Mar 13; 33(3):350-7. PubMed ID: 23775684
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.